Learn about May 2025’s top biotech deals, featuring major collaborations in RNA interference technology, small molecules, and ...

Arrowhead Pharmaceuticals, Inc. today announced that it has dosed the first subjects in a Phase 1/2a clinical trial of ARO-ALK7, the company's investigational RNA interference (RNAi) therapeutic being ...

This triggered the development of RNA interference as a tool, and with it came a myriad of investigations into the function of genes. For researchers working with prokaryotes it is now 1998.

Silexion Therapeutics Corp (NASDAQ:SLXN) has announced breakthrough preclinical results for its next-generation RNA ...

Rona Therapeutics Co. Ltd. has reported preclinical data for its RNA interference (RNAi) therapy RN-026 targeting lipoprotein(a) (Lp[a]).

Arrowhead Pharmaceuticals, Inc.'s deal with Sarepta expands its pipeline, but limited plozasiran market and competition ...

Silexion’s Revolutionary RNAi approach demonstrates powerful anti-tumor activity across three major KRAS-driven cancer types; ...

Results from a clinical trial led by researchers from Queen Mary University of London, published today in JAMA, show that ...

TransCode Therapeutics (NASDAQ: RNAZ) , has appointed Dr. Phillip D. Zamore, a leading figure in RNA interference (RNAi) research and co-founder of A ...

A start-up that launched only 8 months ago has attracted the attention of Biogen, a major developer of neurological drugs.

Biogen will pay City Therapeutics $46m, which includes $16m upfront and $30m investment for a convertible note.